Literature DB >> 19191099

Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?

Olivier Tacca1, Marianne LeHeurteur, Xavier Durando, Marie-Ange Mouret-Reynier, Catherine Abrial, Emilie Thivat, Mathilde Bayet-Robert, Frederique Penault-Llorca, Phillippe Chollet.   

Abstract

This retrospective study analyzed, in metastatic breast cancer (MBC), overall survival (OS) related to each subsequent line of chemotherapy (CT). We evaluated 578 patients with a MBC. Among these patients, 558 patients were stratified according to the number of different CT lines received. Median OS decreased from 22.5 to 12.3 months. Nevertheless, survival was rather stable for subsequent lines after the third line of CT around 8 months. In our study, it appeared useful to give several CT lines when possible. Subsequent lines of CT could have a beneficial effect on the survival for some patients with MBC.

Entities:  

Mesh:

Year:  2009        PMID: 19191099     DOI: 10.1080/07357900802290580

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  5 in total

1.  Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.

Authors:  Raffaella Palumbo; Federico Sottotetti; Alberto Riccardi; Cristina Teragni; Emma Pozzi; Erica Quaquarini; Barbara Tagliaferri; Antonio Bernardo
Journal:  Ther Adv Med Oncol       Date:  2013-11       Impact factor: 8.168

2.  Classification of a palliative care population in a comprehensive cancer centre.

Authors:  Kirstine Skov Benthien; Mie Nordly; Katja Videbæk; Geana Paula Kurita; Hans von der Maase; Helle Timm; Mette Kildevæld Simonsen; Christoffer Johansen; Per Sjøgren
Journal:  Support Care Cancer       Date:  2015-10-13       Impact factor: 3.603

3.  Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.

Authors:  Rebecca Pedersini; Lucia Vassalli; Melanie Claps; Antonella Tulla; Filippo Rodella; Salvatore Grisanti; Vito Amoroso; Elisa Roca; Edda Lucia Simoncini; Alfredo Berruti
Journal:  Oncology       Date:  2018-07-23       Impact factor: 2.935

4.  Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.

Authors:  Xinmin Zhao; Xiaofeng Xu; Qunling Zhang; Zhen Jia; Si Sun; Jian Zhang; Biyun Wang; Zhonghua Wang; Xichun Hu
Journal:  BMC Cancer       Date:  2011-09-22       Impact factor: 4.430

5.  Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

Authors:  Teresa Gamucci; Andrea Michelotti; Laura Pizzuti; Lucia Mentuccia; Elisabetta Landucci; Isabella Sperduti; Luigi Di Lauro; Alessandra Fabi; Giuseppe Tonini; Valentina Sini; Nello Salesi; Ilaria Ferrarini; Angela Vaccaro; Ida Pavese; Enzo Veltri; Luca Moscetti; Paolo Marchetti; Patrizia Vici
Journal:  J Cancer       Date:  2014-03-20       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.